438 related articles for article (PubMed ID: 19260099)
21. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.
Xu G; Kato K; Toki T; Takahashi Y; Terui K; Ito E
J Pediatr Hematol Oncol; 2006 Oct; 28(10):696-8. PubMed ID: 17023834
[TBL] [Abstract][Full Text] [Related]
22. Origins of leukaemia in children with Down syndrome.
Hitzler JK; Zipursky A
Nat Rev Cancer; 2005 Jan; 5(1):11-20. PubMed ID: 15630411
[TBL] [Abstract][Full Text] [Related]
23. A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL.
Haemmerling S; Behnisch W; Doerks T; Korbel JO; Bork P; Moog U; Hentze S; Grasshoff U; Bonin M; Rieß O; Janssen JW; Jauch A; Bartram CR; Reinhardt D; Koch KA; Bandapalli OR; Kulozik AE
Br J Haematol; 2012 Apr; 157(2):180-7. PubMed ID: 22296450
[TBL] [Abstract][Full Text] [Related]
24. Are GATA1 mutations occurring at random in Down syndrome transient leukemia?
Satgé D
Med Hypotheses; 2014 Aug; 83(2):154-9. PubMed ID: 24880866
[TBL] [Abstract][Full Text] [Related]
25. A novel mutation in the GATA1 gene associated with acute megakaryoblastic leukemia in a Korean Down syndrome patient.
Kim IS; Park ES; Lim JY; Ki CS; Chi HS
J Korean Med Sci; 2008 Dec; 23(6):1105-8. PubMed ID: 19119459
[TBL] [Abstract][Full Text] [Related]
26. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome.
Pine SR; Guo Q; Yin C; Jayabose S; Druschel CM; Sandoval C
Blood; 2007 Sep; 110(6):2128-31. PubMed ID: 17576817
[TBL] [Abstract][Full Text] [Related]
27. Induction of hyperproliferative fetal megakaryopoiesis by an N-terminally truncated GATA1 mutant.
Shimizu R; Kobayashi E; Engel JD; Yamamoto M
Genes Cells; 2009 Sep; 14(9):1119-31. PubMed ID: 19682090
[TBL] [Abstract][Full Text] [Related]
28. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
Langebrake C; Creutzig U; Reinhardt D
Klin Padiatr; 2005; 217(3):126-34. PubMed ID: 15858703
[TBL] [Abstract][Full Text] [Related]
29. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
[TBL] [Abstract][Full Text] [Related]
30. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1.
Li Z; Godinho FJ; Klusmann JH; Garriga-Canut M; Yu C; Orkin SH
Nat Genet; 2005 Jun; 37(6):613-9. PubMed ID: 15895080
[TBL] [Abstract][Full Text] [Related]
31. Tetrasomy 21 as a sole acquired abnormality without GATA1 gene mutation in pediatric acute megakaryoblastic leukemia: a case report and review of the literature.
Shin MG; Choi HW; Kim HR; Kim MJ; Baek HJ; Han DK; Kook H; Hwang TJ; Kim HJ; Kim SH; Shin JH; Suh SP; Ryang DW
Leuk Res; 2008 Oct; 32(10):1615-9. PubMed ID: 18372039
[TBL] [Abstract][Full Text] [Related]
32. Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome.
Heald B; Hilden JM; Zbuk K; Norton A; Vyas P; Theil KS; Eng C
Nat Clin Pract Oncol; 2007 Jul; 4(7):433-8. PubMed ID: 17597708
[TBL] [Abstract][Full Text] [Related]
33. GATA 1 mutations as clonal markers of minimal residual disease in acute megakaryoblastic leukemia of Down syndrome--a new tool with significant potential applications.
Hitzler J; Zipursky A
Leuk Res; 2005 Nov; 29(11):1239-40. PubMed ID: 15925405
[No Abstract] [Full Text] [Related]
34. Mosaic Down syndrome-associated acute myeloid leukemia does not require high-dose cytarabine treatment for induction and consolidation therapy.
Kudo K; Hama A; Kojima S; Ishii R; Morimoto A; Bessho F; Sunami S; Kobayashi N; Kinoshita A; Okimoto Y; Tawa A; Tsukimoto I
Int J Hematol; 2010 May; 91(4):630-5. PubMed ID: 20237876
[TBL] [Abstract][Full Text] [Related]
35. Acute megakaryoblastic leukemia in Down syndrome.
Hitzler JK
Pediatr Blood Cancer; 2007 Dec; 49(7 Suppl):1066-9. PubMed ID: 17943965
[TBL] [Abstract][Full Text] [Related]
36. [The role of GATA1 mutation in acute megakaryocytic leukemia].
Ito E
Rinsho Ketsueki; 2006 Nov; 47(11):1415-22. PubMed ID: 17176883
[No Abstract] [Full Text] [Related]
37. Natural history of GATA1 mutations in Down syndrome.
Ahmed M; Sternberg A; Hall G; Thomas A; Smith O; O'Marcaigh A; Wynn R; Stevens R; Addison M; King D; Stewart B; Gibson B; Roberts I; Vyas P
Blood; 2004 Apr; 103(7):2480-9. PubMed ID: 14656875
[TBL] [Abstract][Full Text] [Related]
38. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group.
Kudo K; Kojima S; Tabuchi K; Yabe H; Tawa A; Imaizumi M; Hanada R; Hamamoto K; Kobayashi R; Morimoto A; Nakayama H; Tsuchida M; Horibe K; Kigasawa H; Tsukimoto I;
J Clin Oncol; 2007 Dec; 25(34):5442-7. PubMed ID: 18048827
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia.
Caldwell JT; Edwards H; Dombkowski AA; Buck SA; Matherly LH; Ge Y; Taub JW
PLoS One; 2013; 8(7):e68601. PubMed ID: 23874683
[TBL] [Abstract][Full Text] [Related]
40. Unique clinical and biological features of leukemia in Down syndrome children.
Xavier AC; Ge Y; Taub J
Expert Rev Hematol; 2010 Apr; 3(2):175-86. PubMed ID: 21083461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]